[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"ablation-treatment\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:ablation-treatment":28},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,2,0,[8,46],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":15,"eligibilityCriteria":16,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":19,"targetDuration":4,"studyType":22,"phases":23,"briefSummary":25,"conditions":26,"keywords":30,"overallStatus":33,"whyStopped":4,"lastUpdateSubmitDate":34,"lastUpdatePostDateStruct":35,"startDateStruct":38,"completionDateStruct":40,"leadSponsor":42,"locationsCount":45},"100622942","ablation-of-human-cardiac-fibrillation-based-on-models-of-hierarchical-organization-of-tissue-excitation-100622942",false,"NCT07390175","Ablation of Human Cardiac Fibrillation Based on Models of Hierarchical Organization of Tissue Excitation","Ablación de la fibrilación Cardiaca Humana Basada en Modelos de organización jerárquica de la excitación Tisular.","TerFib","Inclusion Criteria:\n\n* Patients over 18 years of age with persistent AF lasting more than 6 months at the time of the experimental protocol (uninterrupted persistent AF) and clinical indication for an AF ablation procedure.\n\nor\n\n-Patients over 18 years of age with recurrent VF\u002FVT and poor control with conventional pharmacological measures.\n\nExclusion Criteria:\n\n* Lack of patient consent to participate in the study.\n* In patients with persistent AF, contraindication for the use of adenosine.\n* AF\u002FVF\u002FVPT secondary to endocrine-metabolic disorders and\u002For severe systemic disease (thyrotoxicosis, sepsis, pulmonary thromboembolism, etc.).\n* Contraindications for cardiac catheterization (e.g., intracardiac thrombus).\n* Impossibility of remote monitoring using an implantable Holter monitor or implantable defibrillator.","ALL","18 Years",{"count":20,"type":21},78,"ESTIMATED","INTERVENTIONAL",[24],"NA","The mechanisms that maintain persistent atrial fibrillation (AF) in humans remain unknown. In the research project PI18\u002F01268 funded in the previous call for Strategic Action in Health, the group has demonstrated that the hierarchical organization of (i) rotational domains, (ii) frequency domains and (iii) physiological responses to pharmacological provocation with adenosine, allow the identification of domains of high-frequency reentrant activity (hereinafter \"DFASI domains\") maintainers of AF. As a result, the investigators have developed non-invasive technological models and quantitative indices for the efficient localization of these domains, whose therapeutic approach through ablation has allowed to improve the clinical results of the patients studied, safely without increase in complications (Calvo D et al. Sci Rep. 2025 Dec 16;15(1):43892). Likewise, and in response to the objectives of the PI18\u002F01268 project, the investigators have identified hierarchical organization patterns in human ventricular fibrillation (VF) that indicate the existence of universal fibrillatory mechanisms, opening the door to new therapeutic opportunities (Europace 2022;24\\[11\\]:1788-1799).",[27,28,29],"Atrial Fibrillation (AF)","Ablation Treatment","TerFib_Hyerarchy",[31,27,32,29],"Hierarchical organization of tissue excitation","Ablation","RECRUITING","2026-02-18",{"date":36,"type":37},"2026-02-20","ACTUAL",{"date":39,"type":37},"2025-01-20",{"date":41,"type":21},"2026-12-31",{"name":43,"class":44},"Hospital San Carlos, Madrid","OTHER",1,{"id":47,"slug":48,"hasResults":11,"nctId":49,"briefTitle":50,"officialTitle":50,"acronym":4,"eligibilityCriteria":51,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":52,"targetDuration":4,"studyType":22,"phases":54,"briefSummary":55,"conditions":56,"keywords":59,"overallStatus":33,"whyStopped":4,"lastUpdateSubmitDate":64,"lastUpdatePostDateStruct":65,"startDateStruct":67,"completionDateStruct":69,"leadSponsor":71,"locationsCount":45},"100554981","a-prospective-evaluation-of-microwave-ablation-mwa-in-the-treatment-of-relapsed-graves-disease-100554981","NCT06506149","A Prospective Evaluation of Microwave Ablation (MWA) in the Treatment of Relapsed Graves' Disease","Inclusion Criteria:\n\n* (a) age older than 18 years,\n* (b) relapsed Graves' disease despite an adequate ATD treatment for 18 months or more\n* (c) absence of vocal cord immobility\n\nExclusion Criteria:\n\n* (a) patients who prefer or are indicated for surgery,\n* (b) presence of head and\u002For neck disease preventing hyperextension of the neck,\n* (c) history of thyroid cancer or other malignant tumours in the neck region,\n* (d) history of neck irradiation,\n* (e) severe Graves' ophthalmopathy,\n* (f) large compressive goitre,\n* (g) pregnancy or lactation, and\n* (h) any contraindication to intravenous sedation.",{"count":53,"type":21},25,[24],"Graves' disease is the most common cause of hyperthyroidism, with conventional treatment options being anti-thyroid drugs (ATD), radioiodine (RAI) and surgery. For ATD, it has been the first-line treatment over decades. Despite its ability to induce remission, minor side effects such as skin rash, gastrointestinal disturbance and arthralgia occur in around 5% of patients, while serious adverse reactions including agranulocytosis and hepatotoxicity are potentially life threatening. Patients are usually treated with ATD for 12 to 18 months but the relapse rate was reported to be up to 50-60% which these patients would require more definitive treatment options with RAI or thyroidectomy. However, RAI is not preferable in patients with Graves' ophthalmopathy as it could further worsen eye symptoms. RAI may also cause hypothyroidism in a substantial proportion of patients, with a subsequent need for lifelong thyroxine replacement. As for thyroidectomy, it carries an overall 2-10% risk of complications including bleeding, transient or permanent recurrent laryngeal nerve injury and hypoparathyroidism. Due to the drawbacks of the various conventional treatment options, there has been increasing interest in the development of minimally invasive treatment alternatives in recent years. With the evolution of thermal ablative strategies, high-intensity focused ultrasound (HIFU) and radiofrequency ablation (RFA) have been reported as feasible treatment options for relapsed Graves' disease. There has also been increasing reports in the use of microwave ablation (MWA) in the treatment of benign thyroid nodules. MWA works via generation of electromagnetic field and is performed by inserting a microwave antenna into the thyroid gland percutaneously under ultrasound (USG) guidance. The active tip of the antenna causes oscillation of the surrounding water molecules which induces frictional heat and creates a thermal ablative effect. As compared to RFA, MWA is not affected by heat sink effect and may require a shorter treatment time. Similar to other thermal ablative approaches, MWA has the merits of avoiding surgical scar, organ preservation as well as being an ambulatory procedure.",[57,58,28],"Graves Disease","Minimally Invasive Treatment",[60,61,62,63],"Graves disease","Thyroid function","remission","non surgical","2024-07-25",{"date":66,"type":37},"2024-07-29",{"date":68,"type":37},"2023-07-04",{"date":70,"type":21},"2026-06-30",{"name":72,"class":44},"The University of Hong Kong"]